Single Gateway For EMA-HTA Advice May Answer All Stakeholders’ Needs
Executive Summary
The EU research-based pharmaceutical industry has welcomed the launch of a new single gateway for companies to seek parallel scientific advice from the European Medicines Agency and health technology assessment bodies on initial evidence generation and post-authorization data collection. The industry hopes the initiative will help deliver one single evidence package for regulatory and HTA purposes.
You may also be interested in...
EU ATMP Developers Missing Out By Failing To Use Advice On Offer
Regulators and health technology assessment officials in the EU are disappointed that sponsors of advanced therapy medicinal products are not making good use of the joint scientific advice service, which can help converge regulatory and HTA requirements for these products.
EMA and HTA Bodies Launch Three-Year Plan To Better Understand Each Other’s Needs
Understanding how the EMA defines therapeutic indications and how this affects the definition of the treatment-eligible population by HTA bodies is one of the many goals of a new joint workplan by the agency and the EUnetHTA.
EU Pilot Shows Single Drug Development Plan Can Meet Both Regulator And HTA Needs
The EU's pilot exercise in offering drug developers parallel regulatory and health technology assessment (HTA) advice has shown that in most cases a single trial design or drug development plan can be agreed that meets the requirements of the two parties without blurring their respective remits, says a new report from the European Medicines Agency1.